1. Home
  2. ANAB vs DAKT Comparison

ANAB vs DAKT Comparison

Compare ANAB & DAKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANAB
  • DAKT
  • Stock Information
  • Founded
  • ANAB 2005
  • DAKT 1968
  • Country
  • ANAB United States
  • DAKT United States
  • Employees
  • ANAB N/A
  • DAKT N/A
  • Industry
  • ANAB Biotechnology: Pharmaceutical Preparations
  • DAKT Office Equipment/Supplies/Services
  • Sector
  • ANAB Health Care
  • DAKT Industrials
  • Exchange
  • ANAB Nasdaq
  • DAKT Nasdaq
  • Market Cap
  • ANAB 951.1M
  • DAKT 991.0M
  • IPO Year
  • ANAB 2017
  • DAKT 1994
  • Fundamental
  • Price
  • ANAB $36.12
  • DAKT $19.52
  • Analyst Decision
  • ANAB Buy
  • DAKT Strong Buy
  • Analyst Count
  • ANAB 12
  • DAKT 1
  • Target Price
  • ANAB $59.30
  • DAKT $26.00
  • AVG Volume (30 Days)
  • ANAB 365.9K
  • DAKT 485.3K
  • Earning Date
  • ANAB 10-31-2025
  • DAKT 12-03-2025
  • Dividend Yield
  • ANAB N/A
  • DAKT N/A
  • EPS Growth
  • ANAB N/A
  • DAKT 9.66
  • EPS
  • ANAB N/A
  • DAKT 0.23
  • Revenue
  • ANAB $123,164,000.00
  • DAKT $749,361,000.00
  • Revenue This Year
  • ANAB $24.36
  • DAKT $12.94
  • Revenue Next Year
  • ANAB N/A
  • DAKT $7.16
  • P/E Ratio
  • ANAB N/A
  • DAKT $83.36
  • Revenue Growth
  • ANAB 304.17
  • DAKT N/A
  • 52 Week Low
  • ANAB $12.21
  • DAKT $10.24
  • 52 Week High
  • ANAB $38.39
  • DAKT $24.38
  • Technical
  • Relative Strength Index (RSI)
  • ANAB 72.97
  • DAKT 45.45
  • Support Level
  • ANAB $33.01
  • DAKT $19.58
  • Resistance Level
  • ANAB $35.58
  • DAKT $21.00
  • Average True Range (ATR)
  • ANAB 1.67
  • DAKT 0.58
  • MACD
  • ANAB -0.05
  • DAKT -0.04
  • Stochastic Oscillator
  • ANAB 68.61
  • DAKT 24.01

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

About DAKT Daktronics Inc.

Daktronics Inc designs and manufactures electronic scoreboards, programmable display systems, and large-screen video displays for sporting, commercial, and transportation applications. It is engaged in a full range of activities: marketing and sales, engineering and product design and development, manufacturing, technical contracting, professional services, and customer service and support. The company offers a complete line of products, from small scoreboards and electronic displays to large multimillion-dollar video display systems as well as related control, timing, and sound systems. The company has five reportable segments: Commercial, Live Events, High School Park and Recreation, Transportation, and International. The company makes the majority of its revenue from Live events.

Share on Social Networks: